Enrolling

Magnetis MM-4

Measuring Elranatamab's Efficacy, Tolerability, and Safety in Multiple Myeloma

CLINICAL TRIAL

A Phase 1b/2, Open Label Umbrella Study of Elranatamab (PF-06863135), a B-Cell Maturation Antigen (BCMA) CD3 Bispecific Antibody, in Combination with Other Anti-Cancer Treatments in Participants with Multiple Myeloma (MM)[1,2]

Elranatamab is an investigational compound.

These are not the complete inclusion/exclusion criteria. This information is current as of April 2022.

KEY INCLUSION CRITERIA:

- MM diagnosis as defined according to International Myeloma Working Group (IMWG)
- Age ≥18 years
- Relapsed/refractory MM with ≥3 prior lines of therapy
- Refractory to ≥1 immunomodulatory drug (IMiD), ≥1 proteasome inhibitor (PI), and ≥1 anti-CD38 monoclonal antibody (mAb)
- Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1
- Adequate renal, hepatic, cardiac, and bone marrow function

KEY EXCLUSION CRITERIA:

- Active plasma cell leukemia
- Amyloidosis
- Stem cell transplant within 12 weeks prior to enrollment, or active Graft Versus Host Disease (GVHD)
- Polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes (POEMS) syndrome
- Active, uncontrolled bacterial, fungal or viral infection
- Previous treatment with BCMA-bispecific antibody (sub-study A)
- Previous treatment with BCMA-directed therapy (sub-study B)

PATIENT POPULATION (N=105)

SUB-STUDY A

Phase 1

elranatamab + nirogacestat (gamma secretase inhibitor)

Phase 2

elranatamab + nirogacestat (gamma secretase inhibitor)

SUB-STUDY B

Phase 1

elranatamab + lenalidomide + dexamethasone

PRIMARY ENDPOINTS:

SUB-STUDY A:

- Dose limiting toxicity (Phase 1)
- Objective response rate (Phase 2)

SUB-STUDY B:

- Dose limiting toxicity (Phase 1 escalation)
- Frequency of treatment-emergent adverse events (Phase 1 expansion)
- Frequency of laboratory abnormalities (Phase 1 expansion)

Learn more at ClinicalTrials.gov

NCT05090566

References: 1. MagnetisMM-4: Umbrella study of elranatamab (PF-06863135) in combination with anti-cancer treatments in multiple myeloma. ClinicalTrials.gov. Published October 25, 2021. Updated March 11, 2022. Accessed March 15, 2022. https://clinicaltrials.gov/ct2/show/NCT05090566 **2.** Data on file. Pfizer Inc., New York, NY.

Pfizer